MARKET

EXAS

EXAS

EXACT Sci
NASDAQ

Real-time Quotes | Nasdaq Last Sale

128.00
+3.06
+2.45%
After Hours: 129.35 +1.35 +1.05% 19:56 04/13 EDT
OPEN
126.00
PREV CLOSE
124.94
HIGH
129.30
LOW
125.47
VOLUME
1.71M
TURNOVER
--
52 WEEK HIGH
159.54
52 WEEK LOW
63.32
MARKET CAP
21.64B
P/E (TTM)
-23.0847
1D
5D
1M
3M
1Y
5Y
Cathie Wood sees these 2 trends as the next big things after electric vehicles
Wood has big bets on names like Square and PayPal, which dominate the digital wallet space.
CNBC.com · 5h ago
Biopreservation Market Expected To Reach USD 5.63 Billion By 2027 | Key Players: Merck KGaA, ThermoGenesis Holdings, Inc., Thermo Fisher Scientific Inc., and Others
Apr 13, 2021 (AB Digital via COMTEX) -- The global Biopreservation market is forecasted to reach USD 5.63 Billion by 2027, according to a new...
ABNewswire · 5h ago
The global molecular diagnostics market size is projected to reach USD 31.8 billion by 2026 from USD 17.8 billion in 2021, at a CAGR of 12.3%
New York, April 13, Apr 13, 2021 (GLOBE NEWSWIRE via COMTEX) -- New York, April 13, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the...
GlobeNewswire · 20h ago
Cathie Wood Buys Yet Another Workhorse Dip, Also Adds DraftKings, Peloton, Square
Cathie Wood-led Ark Investment Management on Monday bought in more shares of the electric vehicle company Workhorse Group Inc (NASDAQ: WKHS) on a day the stock fell about 6% to $12.36, revealed
Benzinga · 1d ago
Cathie Wood's ARK Invest Posts Fund Purchases For Monday, Apr. 12, 2021: OPEN, ADPT, BLI, MASS, RPTX, U, TXG, FATE, EXAS, DKNG, BEAM, SPFR, SPCE, NNDM, IRDM, DDD, ZM, PTON, LC, RTP, WKHS
Opendoor Technologies (OPEN) - 633,400 Shares Adaptive Biotechnologies (ADPT) - 179,500 Berkeley Lights (BLI)- 45,956 908 Devices (MASS) - 6,603 Repare Therapeutics (RPTX) - 4,597 Unity Software (U) - 124,745 10x
Benzinga · 1d ago
We're really excited that these genomics companies, says Ark's Simon Barnett
Simon Barnett, ARK Invest's genomics analyst, discusses the company's belief in Invitae, its other top picks and why ARK invests the way it does.
CNBC.com · 1d ago
Invitae one of our highest conviction names, says Ark's Simon Barnett
Simon Barnett, ARK Invest's genomics analyst, discusses the company's belief in Invitae, its other top picks and why ARK invests the way it does.
CNBC.com · 1d ago
Phoenix Wealth Advisors Buys Fifth Third Bancorp, Baidu Inc, Teladoc Health Inc, Sells iShares ...
GuruFocus News · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EXAS. Analyze the recent business situations of EXACT Sci through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 17 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EXAS stock price target is 170.63 with a high estimate of 226.00 and a low estimate of 154.00.
EPS
Institutional Holdings
Institutions: 859
Institutional Holdings: 160.01M
% Owned: 94.63%
Shares Outstanding: 169.09M
TypeInstitutionsShares
Increased
206
19.87M
New
145
5.47M
Decreased
171
11.98M
Sold Out
37
5.21M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.86%
Pharmaceuticals & Medical Research
+0.68%
Key Executives
Chairman/President/Chief Executive Officer/Director
Kevin Conroy
Chief Financial Officer
Jeffrey Elliott
Senior Vice President/Chief Administrative Officer/General Counsel/Secretary
D. Scott Coward
Senior Vice President/Chief Scientific Officer
Graham Lidgard
Senior Vice President
Ana Hooker
Senior Vice President
Scott Johnson
Vice President - Operations/General Manager
Pat Setji
General Manager
Torsten Hoof
General Manager
Jake Orville
General Manager
Gisela Paulsen
Director
Paul Clancy
Director
Shacey Petrovic
Independent Director
Thomas Carey
Independent Director
James Doyle
Independent Director
Pierre Jacquet
Independent Director
Daniel Levangie
Independent Director
Freda Lewis-Hall
Independent Director
Kathleen Sebelius
Independent Director
Michael Wyzga
Independent Director
Katherine Zanotti
No Data
  • All
  • Financials
  • Insiders
More
About EXAS
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.

Webull offers kinds of EXACT Sciences Corporation stock information, including NASDAQ:EXAS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXAS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EXAS stock methods without spending real money on the virtual paper trading platform.